Amundi Grows Stake in Danaher Corporation $DHR

Amundi grew its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,053,611 shares of the conglomerate’s stock after purchasing an additional 35,457 shares during the period. Amundi owned approximately 0.43% of Danaher worth $605,153,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. raised its stake in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in shares of Danaher in the 4th quarter valued at approximately $27,000. Sierra Ocean LLC raised its position in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the 1st quarter worth approximately $31,000. Finally, Dunhill Financial LLC grew its position in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of research analyst reports. UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Barclays restated an “overweight” rating and issued a $225.00 target price (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Guggenheim reaffirmed a “buy” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Robert W. Baird increased their price objective on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a report on Friday, July 18th. Finally, Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $246.35.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.20% of the stock is owned by insiders.

Danaher Stock Performance

Shares of DHR stock opened at $203.80 on Wednesday. The stock has a market cap of $145.93 billion, a PE ratio of 43.36, a price-to-earnings-growth ratio of 2.87 and a beta of 0.75. The business has a 50-day simple moving average of $201.97 and a 200-day simple moving average of $199.49. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company earned $1.72 earnings per share. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.